Endocrine Abstracts

With increasing prevalence of type 2 diabetes in India, macrovascular complications are also on the rise. We undertook a retrospective study to evaluate the metabolic profile of type 2 diabetes patients undergoing coronary artery bypass grafting (CABG) at our centre. Clinical data on 672 consecutive patients undergoing elective CABG was included from the hospital data base after informed consent and ethics committee approval. Mean age of the patients was 49.7±9.5 years; 551 were males. Average duration from the time of diagnosis of diabetes to first coronary event was 10.2±2.4 years. 416 patients had BMI>22.9 kg/m² (Asian-Indian cut-off). 110 patients (21.9% men and 3.4% women) were current smokers and another 34 (13.7% men and 1.4% women) had history of smoking. Hypertension was present in 363 (72.8% men and 65.6% women). Glycosylated haemoglobin (HbA1c) was <7% in 154 (23%), between 7% and 9% in 316 (47%) and >9% in 202. Dyslipidemia was present in 531 patients (84.5% men and 83.7% women) with 302 (45.2%) patients having LDL>100 mg/dl, 477 (71%) patients having low HDL and 282 (42.0%) patients having elevated triglycerides. Only 215 (32.3%) were on lipid modifying therapy and of these only 80 (12%) were taking regular treatment. 67% of the patients (43% males and 65% females) had triple vessel disease on coronary angiography. 32% (11% males and 6% females) of patients had evidence of retinopathy on ophthalmic fundus examination and 31% (21% males and 15% females) had microalbuminuria on urine examination. The present study showed high prevalence of metabolic derangements in diabetic patients undergoing CABG with younger age of onset, poor glycemic control and dyslipidemia inspite of being on therapy. This perhaps reflects “treatment inertia” on part of treating physicians and/or lack of awareness on part of the patients.

Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding: No specific grant from any funding agency in the public, commercial or not-for-profit sector.